State Street Corp Bicycle Therapeutics PLC Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Bicycle Therapeutics PLC stock. As of the latest transaction made, State Street Corp holds 86,271 shares of BCYC stock, worth $1.32 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

86,271

Previous 25,872 233.45%

Holding current value

$1.32 Million

Previous $523,000 274.0%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$19.58 - $27.24 $1.18 Million - $1.65 Million	60,399 Added 233.45%	86,271 $1.96 Million
Q1 2024 May 15, 2024	SELL	$16.75 - $26.1 $61,874 - $96,413	-3,694 Reduced 12.49%	25,872 $644,000
Q4 2023 Feb 14, 2024	SELL	$13.29 - $22.2 $83,727 - $139,860	-6,300 Reduced 17.57%	29,566 $534,000
Q3 2023 Nov 14, 2023	BUY	$19.9 - $26.25 $541,280 - $714,000	27,200 Added 313.87%	35,866 $720,000
Q2 2023 Aug 14, 2023	BUY	$18.95 - $28.67 $164,220 - $248,454	8,666 New	8,666 $221,000
Q1 2023 May 15, 2023	SELL	$20.02 - $31.37 $177,397 - $277,969	-8,861 Closed	0 $0
Q4 2022 Feb 14, 2023	BUY	$20.37 - $32.9 $794 - $1,283	39 Added 0.44%	8,861 $262,000
Q3 2022 Nov 15, 2022	SELL	$17.49 - $28.44 $151,323 - $246,062	-8,652 Reduced 49.51%	8,822 $205,000
Q2 2022 Aug 15, 2022	BUY	$12.95 - $46.99 $87,891 - $318,921	6,787 Added 63.51%	17,474 $293,000
Q1 2022 May 16, 2022	BUY	$40.12 - $59.5 $93,599 - $138,813	2,333 Added 27.93%	10,687 $469,000
Q4 2021 Feb 14, 2022	BUY	$41.7 - $61.14 $68,971 - $101,125	1,654 Added 24.69%	8,354 $509,000
Q3 2021 Nov 15, 2021	BUY	$27.95 - $44.24 $187,265 - $296,408	6,700 New	6,700 $279,000

Others Institutions Holding BCYC

# of Institutions

112

Shares Held

41.2M

Call Options Held

39.6K

Put Options Held

24.6K

View Full List

About BICYCLE THERAPEUTICS plc

Ticker BCYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,676,100
Market Cap $455M
Description
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The co...

More about BCYC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Bicycle Therapeutics PLC Transaction History